download haha777
ASAC: Win big by gifting responsibly this holiday season
SAINT PAUL, Minn. (AP) — Rich Byhre had 15 points in St. Thomas' 100-61 victory over Crown (MN) on Sunday. Byhre went 6 of 9 from the field (3 for 4 from 3-point range) for the Tommies (9-4). Ryan Lafferty scored 13 points and added 13 rebounds and six assists. Jermaine Coleman shot 5 for 8, including 2 for 5 from beyond the arc to finish with 12 points. The Polars were led by Rayquan Moore, who posted 23 points. Tyrus Buckner added 13 points and seven rebounds for Crown (MN). Parker Behne also put up eight points. St. Thomas visits Bowling Green in its next matchup on Saturday. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .
How to watch #3 South Carolina vs #8 Duke women’s basketball: Time, TV channel, FREE live stream7NEWS travels with Air New Zealand to the USA to check out Beta Technologies’ electric plane
Dodgers shortstop Jose Hernandez suspended for 2025 ACL season under minor league drug programFinancial services need digital identity stitched together, investors take note
Future of Heterozygous Familial Hypercholesterolemia Drug Market: Analysis and Leadership by Gemphire Therapeutics Inc, Daewoong Co Ltd, Madrigal Pharmaceuticals Inc, Esperion Therapeutics Inc 12-15-2024 02:49 PM CET | Health & Medicine Press release from: STATS N DATA Heterozygous Familial Hypercholesterolemia Drug Market Market Overview and Recent Developments The Heterozygous Familial Hypercholesterolemia (HeFH) Drug Market is experiencing significant growth, characterized by the increasing prevalence of high cholesterol levels and the corresponding need for effective treatment solutions. HeFH is a genetic disorder that leads to elevated levels of low-density lipoprotein (LDL) cholesterol in the bloodstream, resulting in a heightened risk of cardiovascular diseases. This market is not only relevant for healthcare providers but also critical for patients who face the challenges of managing their cholesterol levels effectively. Recent developments in this market have been largely driven by technological advancements, innovative drug formulations, and strategic collaborations among pharmaceutical companies. The advent of new therapies has expanded treatment options, allowing for more tailored patient care and improved health outcomes. Additionally, partnerships between biotech firms and research institutions have accelerated the development of novel drugs and treatment methodologies, reflecting a collaborative approach to tackling this health issue. As the market evolves, stakeholders must remain informed about current trends and dynamics. The integration of digital health technologies, such as telemedicine and mobile health applications, has become increasingly important, enhancing patient engagement and monitoring. The focus on preventive healthcare is also reshaping the landscape, driving demand for effective treatments that prevent the onset of severe complications associated with HeFH. You can access a sample PDF report here: https://www.statsndata.org/download-sample.php?id=24996 Key Growth Drivers and Trends The Heterozygous Familial Hypercholesterolemia Drug Market is being influenced by several critical factors. Sustainability has emerged as a significant driver, as companies are increasingly focused on developing eco-friendly practices in drug manufacturing and distribution. This commitment to sustainability resonates with consumers who are becoming more environmentally conscious and prefer products that align with their values. Digitization of healthcare is another trend shaping the market. The rise of electronic health records and data analytics has facilitated better patient management and treatment personalization. Companies are leveraging these technologies to enhance the development of targeted therapies, thus improving treatment efficacy for HeFH patients. Consumer awareness is also playing a pivotal role in boosting demand for effective treatments. With a growing understanding of the risks associated with high cholesterol, more individuals are seeking medical advice and intervention, leading to an increase in prescriptions for HeFH therapies. Emerging technologies such as artificial intelligence (AI) are set to revolutionize the market by enabling precision medicine approaches. AI can assist in identifying patient-specific treatment plans, optimizing drug formulations, and predicting treatment outcomes based on genetic profiles. Furthermore, product customization is becoming increasingly important, with patients seeking tailored solutions that cater to their unique health needs. Market Segmentation The Heterozygous Familial Hypercholesterolemia Drug Market can be segmented into the following categories: - Segment by Type - Gemcabene Calcium - MGL-3196 - ST-103 - Others - Segment by Application - Clinic - Hospital - Others Each segment plays a crucial role in the overall market dynamics. For instance, Gemcabene Calcium has shown promise in clinical trials, demonstrating significant efficacy in lowering LDL cholesterol levels. MGL-3196, on the other hand, is gaining traction due to its unique mechanism of action, targeting liver metabolism to reduce cholesterol absorption. The application segments highlight the importance of various healthcare settings, with clinics and hospitals being primary venues for patient treatment and management. Get 30% Discount On Full Report: https://www.statsndata.org/ask-for-discount.php?id=24996 Competitive Landscape The competitive landscape of the Heterozygous Familial Hypercholesterolemia Drug Market is marked by the presence of key players who are at the forefront of innovation and market growth. Notable companies include: - Gemphire Therapeutics Inc Gemphire is a leader in the development of therapies aimed at lowering cholesterol levels. Their innovative approach to drug formulation has led to the advancement of new treatment options specifically for HeFH patients. - Daewoong Co Ltd Daewoong is recognized for its commitment to research and development in the field of cardiovascular health. Their strategic partnerships and focus on novel therapies have positioned them as a significant player in the HeFH market. - Madrigal Pharmaceuticals Inc Madrigal is pioneering groundbreaking treatments aimed at addressing lipid disorders. Their focus on metabolic diseases and dedication to clinical research have made them a crucial contributor to the HeFH drug landscape. - Esperion Therapeutics Inc Esperion is well-known for its innovative approaches to lipid management. Their recent product launches and ongoing clinical trials demonstrate their commitment to improving patient outcomes in the HeFH segment. These companies are not only shaping market trends through their innovative products but also driving the overall growth of the HeFH drug market through strategic expansions and collaborations. Opportunities and Challenges The Heterozygous Familial Hypercholesterolemia Drug Market presents numerous opportunities for growth, particularly in untapped regions where healthcare access is limited. Emerging markets are showing a rising demand for cholesterol management solutions, offering pharmaceutical companies the potential to expand their reach. Evolving consumer preferences toward personalized medicine are also creating opportunities. As patients become more informed and proactive about their health, they seek therapies that are tailored to their individual needs, thus driving innovation in drug formulations and delivery methods. However, challenges remain in the form of regulatory constraints that can delay the approval of new therapies. Navigating the complex landscape of drug regulations requires significant resources and expertise. Additionally, operational inefficiencies in the supply chain and talent shortages in the pharmaceutical industry can impede growth. To overcome these challenges, companies must adopt agile operational strategies and invest in workforce development to ensure they have the necessary talent to drive innovation and meet market demands. Technological Advancements Technological advancements are transforming the Heterozygous Familial Hypercholesterolemia Drug Market. The integration of artificial intelligence in drug development is enabling companies to streamline research processes, personalize patient care, and enhance treatment efficacy. AI algorithms can analyze vast datasets to identify patterns and predict patient responses to specific therapies. Moreover, the use of virtual tools is becoming increasingly prevalent in clinical trials, allowing for remote monitoring of participants and real-time data analysis. This not only accelerates the research process but also enhances patient engagement. Internet of Things (IoT)-driven systems are also playing a crucial role in patient management. Wearable devices that monitor cholesterol levels and health metrics can provide valuable insights, enabling healthcare providers to make informed decisions about treatment adjustments. Research Methodology and Insights STATS N DATA employs a robust research approach to provide accurate insights into the Heterozygous Familial Hypercholesterolemia Drug Market. Utilizing both top-down and bottom-up methodologies, our research team conducts comprehensive primary and secondary research to gather data from industry experts, market participants, and relevant literature. Triangulation techniques are applied to validate findings, ensuring that our insights are not only reliable but also actionable for stakeholders seeking to navigate this dynamic market. By leveraging a combination of quantitative and qualitative research methods, STATS N DATA is committed to delivering comprehensive market analysis that informs strategic decision-making. In conclusion, the Heterozygous Familial Hypercholesterolemia Drug Market is poised for significant growth, driven by technological advancements, evolving consumer preferences, and a commitment to innovation from key industry players. As the market continues to evolve, stakeholders must stay informed and agile to capitalize on emerging opportunities and address the challenges ahead. For customization requests, please visit: https://www.statsndata.org/request-customization.php?id=24996 Access the full report analysis here: https://www.statsndata.org/report/heterozygous-familial-hypercholesterolemia-drug-market-24996 Related Reports: Social Content Management Platform Market https://www.statsndata.org/report/social-content-management-platform-market-54330 Automated and Convenient Transportation Market https://www.statsndata.org/report/automated-and-convenient-transportation-market-41666 Voiceprint Recognition (VPR) Technology Market https://www.statsndata.org/report/voiceprint-recognition-vpr-technology-market-49060 Radiation Hardened Solution Market https://www.statsndata.org/report/radiation-hardened-solution-market-58256 Employee Training Platform Market https://www.statsndata.org/report/employee-training-platform-market-43607 John Jones Sales & Marketing Head | Stats N Data Phone: +1 (315) 642-4324 Email: sales@statsndata.org Website: www.statsndata.org STATS N DATA is a trusted provider of industry intelligence and market research, delivering actionable insights to businesses across diverse sectors. We specialize in helping organizations navigate complex markets with advanced analytics, detailed market segmentation, and strategic guidance. Our expertise spans industries including technology, healthcare, telecommunications, energy, food & beverages, and more. Committed to accuracy and innovation, we provide tailored reports that empower clients to make informed decisions, identify emerging opportunities, and achieve sustainable growth. Our team of skilled analysts leverages cutting-edge methodologies to ensure every report addresses the unique challenges of our clients. At STATS N DATA, we transform data into knowledge and insights into success. Partner with us to gain a competitive edge in today's fast-paced business environment. For more information, visit https://www.statsndata.org or contact us today at sales@statsndata.org This release was published on openPR.
US agencies should use advanced technology to identify mysterious drones, Schumer saysDodgers shortstop Jose Hernandez suspended for 2025 ACL season under minor league drug program
Federal prosecutors seek records from company that deployed AI weapons scanner on NYC subwayTo play Maria Callas, Angelina Jolie had to learn how to breathe again
Trump’s tariff threat a grim reminder of turbulent trade in first administrationBOSTON — After weeks of fear and bewilderment about the drones buzzing over parts of New York and New Jersey, elected officials are urging action to identify and stop the mysterious flights. “There’s a lot of us who are pretty frustrated right now,” Rep. Jim Himes, D-Conn., the top Democrat on the House Intelligence Committee, said on “Fox News Sunday.” “'We don’t know’ is not a good enough answer,” he said. National security officials have said the drones don’t appear to be a sign of foreign interference or a public safety threat. But because they can’t say with certainty who is responsible for the sudden swarms of drones over parts of New Jersey, New York and other eastern parts of the U.S. — or how they can be stopped — has led leaders of both political parties to demand better technology and powers to deal with the drones. Sen. Chuck Schumer called Sunday for the U.S. Department of Homeland Security to deploy better drone-tracking technology to identify the drones and their operators. “New Yorkers have tremendous questions about it,” Schumer, the Senate Majority leader, told reporters about the drone sightings. “We are going to get the answers for them.” The federal government did little to answer those questions in its own media briefings Sunday morning. “There’s no question that people are seeing drones,” U.S. Homeland Security Secretary Alejandro Mayorkas told ABC’s George Stephanopoulos. “But I want to assure the American public that we are on it. We are working in close coordination with state and local authorities.” Some of the drones reported above parts of New York and New Jersey have turned out to be “manned aircraft that are commonly mistaken for drones,” Mayorkas said. “We know of no foreign involvement with respect to the sightings in the Northeast. And we are vigilant in investigating this matter.” Last year, federal aviation rules began requiring certain drones to broadcast their remote identification, including the location of their operators. It’s not clear whether that information has been used to determine who is behind the drones plaguing locations over New York and New Jersey. Mayorkas’ office didn’t respond to questions about whether they’ve been able to identify drones using this capability. Schumer wants the federal government to use a recently declassified radio wave technology in New York and New Jersey. The radio wave detector can be attached to a drone or airplane and can determine whether another flying object is a bird or a drone, read its electronic registration, and follow it back to its landing place. Schumer said state and local authorities do not have the authority to track drones. On Sunday, New York Gov. Kathy Hochul said federal officials were sending a drone detection system to the state. “This system will support state and federal law enforcement in their investigations,” Hochul said in a statement. The governor did not immediately provide additional details, including where the system will be deployed. Dozens of mysterious nighttime flights started last month over parts of New Jersey, raising concerns among residents and officials. Part of the worry stems from the flying objects initially being spotted near the Picatinny Arsenal, a U.S. military research and manufacturing facility and over President-elect Donald Trump’s golf course in Bedminster. Drones are legal in New Jersey for recreational and commercial use, but they are subject to local and Federal Aviation Administration regulations and flight restrictions. Operators must be FAA certified. Drones are now being reported all along the northern East Coast, with suspicious sightings in Connecticut, Massachusetts, Pennsylvania and Virginia, according to news reports. Some U.S. political leaders, including Trump, have called for stronger action against these drones, including shooting them down. Certain agencies within the Department of Homeland Security have the power to “incapacitate” drones, Mayorkas said Sunday. “But we need those authorities expanded,” he said. A bill before the U.S. Senate would enhance some federal agencies’ authority and give new abilities to local and state agencies to track drones. It would also start a pilot program allowing states and local authorities to disrupt, disable or seize a drone without prior consent of the operator. “What the drone issue points out are gaps in our agencies, gaps in our authorities between the Department of Homeland Security, local law enforcement, the Defense Department.," said Rep. Mike Waltz, R-Fla., Trump’s pick to be his national security adviser, speaking on CBS’ “Face the Nation” on Sunday. "Americans are finding it hard to believe we can’t figure out where these are coming from.’’
US agencies should use advanced technology to identify mysterious drones, Schumer says'The mind changes very quickly with the situation' - Kilkenny All-Ireland winner on secret to managing setbacksFresh protests in Georgia after PM vows to 'eradicate' opposition
December 12, 2024 – Coins.ph , the Philippines’ largest digital asset platform, has achieved key milestones in its global expansion, including launching early access for Australian users and an upcoming launch in Brazil. This comes on the back of record numbers and strong performance for Coins.ph this year. Not only has trading volume on the exchange grown 10 times, the company is projecting to close the year out with revenue being 4 times that of the prior year. Coins.ph is not stopping there. Under the leadership of CEO Wei Zhou, Coins.ph has grown from a homegrown pioneer to a global player with its international platform Coins.xyz , and aims to set the standard for regulated cryptocurrency services globally. Launches in Australia and Brazil In Australia, Coins is partnered with Monochrome, which launched Australia’s first direct spot Bitcoin and Ethereum ETFs. Together, the two are delivering trusted and compliant services to meet the needs of Australian crypto users. In line with this, Coins.xyz Australia is connected to the country’s banking rails so users can seamlessly cash in and withdraw Australian Dollars (AUD). It also boasts AUD trading pairs for those that want to trade crypto with AUD directly. In Brazil, one of the world’s largest and fastest-growing crypto markets, Coins.xyz will be opening its doors to users soon and launching its fiat on and offramps next month. “We promised global expansion, and now it’s happening,” said Wei Zhou, CEO of Coins.ph and Coins.xyz. “Australia and Brazil are key markets for our vision of connecting the world through regulated and accessible digital asset services. It’s our mission that Coins.ph, through Coins.xyz, distinguishes itself as a standard bearer for trust, compliance, and security in the global crypto space.” A Rare Filipino Success Story on the Global Stage Coins.ph is rewriting the narrative for Philippine tech startups. Very few have managed to establish a significant global presence, and Coins.ph has taken tangible steps towards this. “Our investments in technology and product over the past two years have catapulted our capabilities and paved the way for Coins.ph to become truly global,” Zhou said. Coins.ph’s expansion through Coins.xyz is a testament to the caliber of Filipino talent and as it conquers new market. Not only is the company looking to set the benchmark for regulated crypto services worldwide, it is also proving to builders across the country that a Philippine-born platform can aspire to become a contender worldwide. Being business-savvy should be fun, attainable and A+. BMPlus is BusinessMirror's digital arm with practical tips & success stories for aspiring and thriving millennial entrepreneurs.None
DY Patil University is currently accepting applications for a wide range of undergraduate, postgraduate, and doctoral programmes for the 2025 academic session. Interested candidates can apply online for the various programmes offered by the university's distinguished schools. Programmes Offered Vijay Patil School of Management BBA/MBA Bachelor of Accounting and Finance (BAF) School of Sports, Exercise & Nutrition Sciences Bachelor of Sports Science (BSS) Master of Sports Science (MSS) School of Public Health Master of Public Health (MPH) Master of Public Policy (MPP) Executive MPH Bachelor of Public Health BSc Environment & Sustainability School of Architecture BArch/MArch BSc Product Design BSc Interior Design Bachelor of Visual Arts School of Occupational Therapy BOT/MOT School of Pharmacy BPharm/DPharm/MPharm Schools of Medicine MBBS/MD/MS/DM/MCh/Fellowships School of Dentistry BDS/MDS School of Ayurveda BAMS/MD/MS School of Physiotherapy BPT/MPT BSc Forensic Sciences BSc Defence and Strategic Studies BSc Homeland Security BSc Actuarial Science MSc Actuarial Science School of Engineering (RAIT) BTech/MTech/MBA Tech/PhD BTech Cloud Computing BTech Nano Science & Technology BTech Cyber Security & Digital Forensics School of Law BALLB/BBALLB (Hons)/BCom LLB/LLB/LLM School of Allied Health Sciences BSc/MSc School of Nursing BSc Nursing/MSc Nursing/PhD Nursing School of Hospitality & Tourism Studies BSc Hospitality/BSc Culinary Studies BSc Cruise Line Studies/ BSc Event Studies MSc Tourism Studies School of Humanities & Sciences Library Science (BLibSc/MLibSc) School of Creative Studies BA Communication & Media Studies BSc Fashion & Apparel Studies BSc Multimedia, Animation & VFX Application Fee Undergraduate programmes: Rs 1,550 Postgraduate programmes: Rs 2,150 Doctoral programmes: Rs 3,150 Applicants are advised to submit only one application. Multiple submissions will lead to the rejection of all applications from the candidate. Please ensure that the application form is complete, as it is not editable once submitted. Applicants are encouraged to take a printout of the confirmation page and retain a copy of the proof of processing fee payment for future reference. For more details and to apply, visit the official website of DY Patil University. Track Education News , Exam updates , Campus , Study Abroad related news live on NDTV.comVictorian jockey Laura Lafferty has opened up on rebuilding her health and life following a fall that left her in an induced coma. The 25-year-old fell off The Praised One from the lead of a 1400m race at Ballarat in October, sent tumbling as the rest of the field made its way past her. Lafferty suffered two collapsed lungs, Grade 4 lacerations to her liver and spleen, severe body bruising, concussion, a broken foot and two broken ribs. Know the news with the 7NEWS app: Download today Lafferty can still recall the “really nice, sunny day” and exactly who she was talking to behind the gates — “then everything changed”. “The last thing I remember was coming out of the gates and making my way to the front of the field,” she told Racing.com. “I had thought that the fall had happened 200m out of the gates but I don’t really remember. “But my horse had shied at something on the inside, and I’d come off the side of it. That’s the last thing I remember. “I don’t remember making it from Ballarat Racecourse to Ballarat hospital. “I woke up again at Ballarat Hospital, where they had said they were going to put me in an induced coma, and then obviously don’t remember until I’d woken up in Melbourne Alfred.” Still “so thankful” for trackside paramedic Mick saving her life, Lafferty said she and her family do not relive the accident itself. “It’s still pretty new, pretty raw,” she said. “My biggest challenge is definitely mentally coming to terms with not being able to even run, let alone work. “That’s why I’m putting steps in place to be able to get through the next 12 months, just doing a course at RMIT, setting those goals, booking physio every week just gets me through every week. “It’s a mental game at this stage.” The mind and body are both a work in progress but improvements are clear on the physical front, with Lafferty crediting many people — and one in particular — for her fightback. “The doctors and specialists have been really happy,” Lafferty said. “My mum, she’s stayed with me, taken me to all my appointments. She’s just literally done everything so I wouldn’t be as far along in the recovery journey if it weren’t for her.” Lafferty is aiming to compete in a triathlon midway through next year but horse racing has taken a back seat to a more realistic proposition. “My goal in regards to horse riding would be get back show jumping in beyond six months,” she said.